What's new? Log in Free sign up

Natera (NTRA)

Company Profile

Company profile

Ticker

NTRA

Exchange

Website

CEO

Mr. Steven Leonard Chapman

Incorporated

Location

Fiscal year end

Industry (SIC)

Services - Medical Laboratories

Quest Diagnostics • Laboratory Corporation of America • Fortrea • GRAIL • Akumin • Burning Rock Biotech Limited • Guardant Health • Exact Sciences • Genomic Health • Invitae ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NTRA stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$165.80

Low target

$135.00

High target

$200.00

Canaccord Genuity

Leerink Partners

Latest filings (excl ownership)

View all

Departure of Directors or Certain Officers

Quarterly report

12 Nov 24

Natera Reports Third Quarter 2024 Financial Results

Registration of securities for employees

Departure of Directors or Certain Officers

Additional proxy soliciting materials

Quarterly report

9 May 24

Natera Reports First Quarter 2024 Financial Results

Annual report to shareholders

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Jonathan Sheena

Notice of proposed sale of securities

Matthew Rabinowitz

Notice of proposed sale of securities

Rowan E Chapman

Solomon Moshkevich

Notice of proposed sale of securities

Notice of proposed sale of securities

Matthew Rabinowitz

Financial summary

Financial statements Chart NTRA financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	892.84 mm	892.84 mm	892.84 mm	892.84 mm	892.84 mm	892.84 mm
Cash burn (monthly)	(no burn)	(no burn)	13.11 mm	25.76 mm	1.40 mm	5.41 mm
Cash used (since last report)	n/a	n/a	36.53 mm	71.78 mm	3.90 mm	15.06 mm
Cash remaining	n/a	n/a	856.31 mm	821.06 mm	888.94 mm	877.78 mm
Runway (months of cash)	n/a	n/a	65.3	31.9	635.0	162.4

Beta Read what these cash burn values mean

Financial data from Natera earnings reports.

Institutional ownership, Q3 2024

NTRA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	488	473	+3.2%
Opened positions	68	95	-28.4%
Closed positions	53	37	+43.2%
Increased positions	174	182	-4.4%
Reduced positions	193	145	+33.1%

13F shares	Current	Prev Q	Change
Total value	13.89 tn	12.34 tn	+12.6%
Total shares	124.02 mm	142.38 mm	-12.9%
Total puts	189.70 k	269.10 k	-29.5%
Total calls	303.40 k	406.90 k	-25.4%
Total put/call ratio	0.6	0.7	-5.5%

Largest owners	Shares	Value	Change
Vanguard	11.44 mm	$1.45 tn	+1.4%
BLK BlackRock	8.23 mm	$1.05 tn	NEW
JPM JPMorgan Chase & Co.	4.63 mm	$588.04 bn	-23.6%
Farallon Capital Management	4.56 mm	$578.55 bn	+2.2%
Fred Alger Management	4.01 mm	$509.32 bn	-23.8%
Alger Associates	4.01 mm	$508.44 mm	-55.3%
Duquesne Family Office	3.57 mm	$452.81 mm	+80.6%
STT State Street	3.49 mm	$443.61 bn	-2.2%
T. Rowe Price	2.87 mm	$364.42 mm	+442.8%
Wellington Management	2.80 mm	$355.49 bn	+205.4%

Largest transactions	Shares	Bought/sold	Change
Lord, Abbett & Co.	1.51 mm	-13.51 mm	-90.0%
BLK BlackRock	8.23 mm	+8.23 mm	NEW
BLK BlackRock	0.00	-6.77 mm	EXIT
Alger Associates	4.01 mm	-4.96 mm	-55.3%
T. Rowe Price	2.87 mm	+2.34 mm	+442.8%
Wellington Management	2.80 mm	+1.88 mm	+205.4%
Duquesne Family Office	3.57 mm	+1.59 mm	+80.6%
JPM JPMorgan Chase & Co.	4.63 mm	-1.43 mm	-23.6%
Norges Bank	0.00	-1.32 mm	EXIT
Fred Alger Management	4.01 mm	-1.25 mm	-23.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NTRA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	Yes	Yes	168.023	496	83.34 k	46,282
18 Dec 24	Sheena Jonathan	Common Srock	Sell	Dispose S	Yes	Yes	167.074	852	142.35 k	46,778
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	Yes	Yes	166.0075	152	25.23 k	47,630
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	Yes	Yes	168.0445	303	50.92 k	46,282
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	Yes	Yes	167.1798	959	160.33 k	46,585
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	Yes	Yes	166.1766	238	39.55 k	47,544
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	No	Yes	168.1456	537	90.29 k	257,072
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	No	Yes	167.2499	1,825	305.23 k	257,609
18 Dec 24	Sheena Jonathan	Common Stock	Sell	Dispose S	No	Yes	165.9748	338	56.10 k	259,434
13 Dec 24	Matthew Rabinowitz	Common Stock	Sell	Dispose S	No	Yes	168.3547	5,300	892.28 k	2,389,180

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Billionaire Stanley Druckenmiller's latest large wager on biotech company Natera Inc has paid off, with his stake now exceeding $575 million.

JP Morgan Maintains Overweight on Natera, Raises Price Target to $200

JP Morgan analyst Julia Qin maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $160 to $200.

Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites

SAGITTARIUS is Natera's first interventional trial using SignateraTM to select patients for targeted therapy in early-stage colon cancerApproximately 700-900 patients expected to be enrolled across more than 20

Looking Into Natera's Recent Short Interest

Natera Announces That Obstetrics & Gynecology Published The Company's Clinical Validation Study On Its Cell-Free DNA Fetal RhD Noninvasive Prenatal Test

Press releases

From Benzinga Pro

Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Amended complaint asserts infringement of U.S. Patent Nos. ‘596 and ‘454 by the modified version of NeoGenomics' RaDaR assay Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing,

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

Natera Issues Statement on Guardant Health Litigation

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.